(secondQuint)2nd-line Treatment of Metastatic Colorectal Cancer.

 Eligible patients are randomly allocated to receive either bevacizumab with raltitrexed and oxaliplatin combination or bevacizumab with FOLFOX 6 combination.

 Random allocation schedule is performed using a minimization technique for the following stratification factors: - Center - Number of metastatic sites: 1 versus > 1 - Bevacizumab-based first-line therapy: Yes versus No.

 2nd-line Treatment of Metastatic Colorectal Cancer@highlight

This phase 2 trial aims to evaluate the continued use of bevacizumab with raltitrexed and oxaliplatin combination versus FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer whose disease has progressed after irinotecan-based chemotherapy.

